HepQuant to Present Poster as a Finalist in the RESI San Francisco Innovation Challenge 2018
DENVER (January 2nd, 2017) — HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it will present a poster at the RESI San Francisco Innovation Challenge 2018, being held on January 9th, 2018 in San Francisco. As finalist in this challenge, HepQuant will present its poster at the Marine’s Memorial Club & Hotel in San Francisco, CA. The RESI Conference is an investor and partnering conference focused on early-stage companies attended by biotechnology and pharmaceutical executives and investment professionals.
Details about this event:
Date: Tuesday, January 9th, 2018
Time: all day – 7:00am – 6:00 pm
Track: Exhibit Hall (above partnering hall)
Senior executives at HepQuant will be available for one-on-one meetings for attendees at the RESI San Francisco Conference. Senior executives will also be attending the 36th Annual J.P. Morgan Conference and available to meet from Monday, January 8th – Thursday, January 11th.
HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.
Brad Everson, CBDO
Ph: (303) 923 – 2150 | E: [email protected]
Media: Tom Kennedy
E: [email protected] | M: (720) 507-4164